Publicaciones (19) Publicaciones de JUAN PABLO FUSCO MORALES

2024

  1. Whole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma

    eBioMedicine, Vol. 102

2023

  1. Prostate Cancer: Management of Biochemical Recurrence after Surgery

    Archivos espanoles de urologia, Vol. 76, Núm. 10, pp. 733-745

2021

  1. Whole exome sequencing characterization of individuals presenting extreme phenotypes of high and low risk of developing tobacco-induced lung adenocarcinoma

    Translational Lung Cancer Research, Vol. 10, Núm. 3, pp. 1327-1337

2020

  1. Spanish risk management framework across 17 radiation oncology centers during COVID-19 pandemic

    Radiotherapy and Oncology, Vol. 148, pp. 267-269

2019

  1. Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer

    International Journal of Cancer, Vol. 145, Núm. 7, pp. 1991-2001

2018

  1. Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer

    Cancer Medicine, Vol. 7, Núm. 7, pp. 3474-3483

2017

  1. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients

    Annals of Oncology, Vol. 28, Núm. 8, pp. 1988-1995

  2. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2016

  1. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value

    Tumor Biology, Vol. 37, Núm. 10, pp. 13687-13694

  2. Tumor-Produced Interleukin-8 Attracts human myeloid-derived suppressor cells and elicits extrusion of Neutrophil Extracellular Traps (NETs)

    Clinical Cancer Research, Vol. 22, Núm. 15, pp. 3924-3936

2015

  1. Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis

    Journal of Translational Medicine, Vol. 13, Núm. 1

  2. Safety and efficacy of temsirolimus under compassionate use in heavily pretreated patients with poor-prognosis solid tumors

    Minerva Chirurgica

  3. Tratamiento del cáncer de próstata en función de la esperanza de vida, la comorbilidad y las guías de práctica clínica

    Anales del sistema sanitario de Navarra, Vol. 38, Núm. 3, pp. 463-464

  4. Utility of delayed reading of intradermal test in carboplatin-induced drug hypersensitivity

    Annals of Allergy, Asthma and Immunology, Vol. 114, Núm. 6, pp. 534-535

2014

  1. Epidermal growth factor receptor targeting in non-small cell lung cancer: Revisiting different strategies against the same target

    Current Drug Targets, Vol. 15, Núm. 14, pp. 1273-1283

2013

  1. Clinical management of small-cell carcinoma of the urinary tract: A 10-year single-center's experience

    Clinical Genitourinary Cancer, Vol. 11, Núm. 2, pp. 168-174

  2. Neurological and cytological response as potential early predictors of time-to-progression and overall survival in patients with leptomeningeal carcinomatosis treated with intrathecal liposomal cytarabine: A retrospective cohort study

    Journal of Neuro-Oncology

  3. Safety and efficacy of maintenance therapy with a nonspecific cytochrome P17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castration-resistant prostate cancer

    Clinical Genitourinary Cancer, Vol. 11, Núm. 2, pp. 78-84

2011

  1. EGFR mutation testing in nonsmall cell lung cancer patients by using cytology specimens: When the tissue is no longer the issue

    Cancer Cytopathology